NOVEL STRATEGIES FOR OVARIAN CANCER PREVENTION
预防卵巢癌的新策略
基本信息
- 批准号:8357782
- 负责人:
- 金额:$ 4.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectCancer PatientCellsDataDetergentsDevelopmentDiagnosisDiseaseDown-RegulationEarly DiagnosisElementsEpitheliumFundingGenesGrantHistone AcetylationIndiumMalignant neoplasm of ovaryMessenger RNAMethylationMicroarray AnalysisMolecular AnalysisNational Center for Research ResourcesOvarianOvaryPrevention strategyPrimatesPrincipal InvestigatorResearchResearch InfrastructureResourcesRiskSourceStagingSurfaceSurvival RateSystemTherapeuticTranslatingUnited States National Institutes of HealthWomanbaseclinical applicationcostimprovednonhuman primatenovel strategiesoutcome forecastovarian cancer preventionprogramstreatment strategy
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
The ovarian surface epithelium (OSE) is the source of most ovarian cancers in women, yet comprises less than 1/1,000th of the ovary. The basis for OSE transformation is poorly understood, hindering the development of improved strategies for treatment. Since the prognosis for ovarian cancer declines dramatically when the disease is diagnosed at later stages (95% cure rate at stage I, but a 5-year survival rate of only 10% at stage IV), strategies for prevention and early detection may offer the best hope of reducing the number of fatalities from ovarian cancer. We are developing two novel strategies for ovarian cancer prevention: first, we seek to eliminate the OSE completely, using detergent and mild abrasion (epitheliectomy); second, we wish to modulate FANCD2 expression in the OSE. This project more broadly seeks to establish a research program whereby microarray and molecular analysis of OSE cells from healthy, at risk, and cancer
patients will identify key elements in OSE transformation. The nonhuman primate system will be used to evaluate these elements as candidates for therapeutic manipulation, and the data will be translated into clinical application for ovarian cancer prevention and early
detection therapies. Current data indicate the OSE may be effectively removed without impairing ovarian function. In addition, we have eliminated FANCD2 gene methylation and histone acetylation as probable mechanisms for its downregulation in at-risk women. Ongoing research will determine whether miRNA's are affecting FANCD2 mRNA levels.
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
卵巢表面上皮(OSE)是大多数女性卵巢癌的来源,但仅占卵巢的不到1/1000。人们对OSE转化的基础知之甚少,阻碍了改进治疗策略的发展。由于晚期卵巢癌的预后显著下降(I期治愈率95%,但IV期5年生存率仅为10%),预防和早期发现策略可能是减少卵巢癌死亡人数的最大希望。我们正在开发两种预防卵巢癌的新策略:第一,我们寻求完全消除OSE,使用洗涤剂和轻度擦伤(上皮切除);第二,我们希望调节OSE中FANCD2的表达。这个项目更广泛地寻求建立一个研究计划,通过该计划对健康的、有风险的和癌症的OSE细胞进行微阵列和分子分析
患者将确定OSE转型的关键要素。非人灵长类动物系统将被用来评估这些元素作为治疗操作的候选者,数据将被转化为卵巢癌预防和早期临床应用。
侦测疗法。目前的数据表明,OSE可以在不损害卵巢功能的情况下被有效地去除。此外,我们已经排除了FANCD2基因甲基化和组蛋白乙酰化作为其在高危女性中下调的可能机制。正在进行的研究将确定miRNA是否影响FANCD2的mRNA水平。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jay W Wright其他文献
Jay W Wright的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jay W Wright', 18)}}的其他基金
BIOLOGY OF THE PRIMATE OVARIAN SURFACE EPITHELIUM
灵长类动物卵巢表面上皮的生物学
- 批准号:
8357773 - 财政年份:2011
- 资助金额:
$ 4.36万 - 项目类别:
BIOLOGY OF THE PRIMATE OVARIAN SURFACE EPITHELIUM
灵长类动物卵巢表面上皮的生物学
- 批准号:
8173238 - 财政年份:2010
- 资助金额:
$ 4.36万 - 项目类别:
BIOLOGY OF THE PRIMATE OVARIAN SURFACE EPITHELIUM
灵长类动物卵巢表面上皮的生物学
- 批准号:
7958496 - 财政年份:2009
- 资助金额:
$ 4.36万 - 项目类别:
BIOLOGY OF THE PRIMATE OVARIAN SURFACE EPITHELIUM
灵长类动物卵巢表面上皮的生物学
- 批准号:
7715990 - 财政年份:2008
- 资助金额:
$ 4.36万 - 项目类别:
ESTROGEN-MEDIATED CELL CYCLE ARREST VIA P53 AND P21
通过 P53 和 P21 雌激素介导的细胞周期停滞
- 批准号:
7715991 - 财政年份:2008
- 资助金额:
$ 4.36万 - 项目类别:
Biology of the Primate Ovarian Surface Epithelium
灵长类动物卵巢表面上皮的生物学
- 批准号:
7357490 - 财政年份:2007
- 资助金额:
$ 4.36万 - 项目类别:
相似海外基金
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
- 批准号:
10733315 - 财政年份:2023
- 资助金额:
$ 4.36万 - 项目类别:
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival
SQLE 和甾醇导致 ER 乳腺癌患者生存率的种族差异
- 批准号:
10571020 - 财政年份:2023
- 资助金额:
$ 4.36万 - 项目类别:
Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.
建立组件的工业化生产,使癌症患者群体能够更容易地获得 PET 成像。
- 批准号:
10698218 - 财政年份:2023
- 资助金额:
$ 4.36万 - 项目类别:
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft Models
华盛顿大学 PDX 开发和试验中心 - Abemaciclib 联合 Olaparib 在卵巢癌和乳腺癌患者异种移植模型中的评估
- 批准号:
10582164 - 财政年份:2022
- 资助金额:
$ 4.36万 - 项目类别:
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
- 批准号:
10039823 - 财政年份:2022
- 资助金额:
$ 4.36万 - 项目类别:
EU-Funded
Convening a gynecologic cancer patient advisory group to adapt a digital health tool
召集妇科癌症患者咨询小组以采用数字健康工具
- 批准号:
460767 - 财政年份:2022
- 资助金额:
$ 4.36万 - 项目类别:
Miscellaneous Programs
Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
增强癌症患者在临终时最佳使用抗血栓治疗的能力
- 批准号:
10038000 - 财政年份:2022
- 资助金额:
$ 4.36万 - 项目类别:
EU-Funded
Longitudinal mixed method investigation of social networks and affective states as determinants of smoking behavior among cancer patient
社会网络和情感状态作为癌症患者吸烟行为决定因素的纵向混合方法调查
- 批准号:
10513670 - 财政年份:2021
- 资助金额:
$ 4.36万 - 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
- 批准号:
10598311 - 财政年份:2021
- 资助金额:
$ 4.36万 - 项目类别:
Improving the translational value of head and neck cancer patient-in-mouse models
提高头颈癌小鼠模型的转化价值
- 批准号:
10442585 - 财政年份:2021
- 资助金额:
$ 4.36万 - 项目类别: